Half a year later, the three pharmaceutical companies will finally be sold

In the past six months, Yuheng sold three pharmaceutical companies, but the dust has not settled.
July 3, Yuheng Pharmaceuticals announced the sale of a wholly owned subsidiary, Shanghai Huato Pharmaceutical Technology Development Co., Ltd., Tibet Yuheng Sunshine Pharmaceutical Co., Ltd., Shanxi Pude Pharmaceutical Co., Ltd., 100% of the major asset restructuring announcement.
According to the announcement, the Company's shares have been suspended since the market opened on February 22, 2018 and have disclosed the Suspension Notice on the Planning of Major Asset Restructuring, and have committed to seek suspension for a period of not more than one month, i.e. to seek disclosure of a material asset restructuring plan that meets the requirements by March 21, 2018.
However, due to the transaction involving due diligence and other heavy workload, restructuring program still needs to be further demonstrated and improved, the company can not complete the relevant commitments, the company disclosed the announcement of the extension of the re-licensing, and continue to promote the major asset restructuring work.Slimming
public information shows that: Yu heng pharmaceutical industry was established in March 2000, to the pharmaceutical industry as the main line, to the pharmaceutical business as the core, covering scientific research, production, marketing and other fields.
Since its listing, it has enriched the company's product line through extended mergers and acquisitions, cooperative agents, independent research and development, overseas introduction and other ways to achieve the expansion from the initial narrow single orthopaedic treatment field to the existing cardiovascular and other large therapeutic areas.
and its wholly-owned subsidiary, Shanghai Huato Pharmaceutical Technology Development Co., Ltd., is engaged in the development and innovation of the pharmaceutical technology industry, including chemical and natural drug research and development and technology transformation, with independent intellectual property rights of new drug research and development and modernization of Traditional Chinese medicine as the focus of development.
Another selling company is Tibet Yuheng Sunshine Pharmaceutical Co., Ltd., the company's main business scope in chemical drugs, traditional Chinese medicine, antibiotic preparations, chemical raw materials sales, etc. (only Harbin Yuheng Pharmaceutical Co., Ltd. independently produced varieties and access to the general agent of DNA injections, sodium surasirin Shubatan)
and Shanxi Pude Pharmaceutical Co., Ltd. now has three production plants, nine production lines, 650 employees. Existing production lines can produce 80 million powder needles / year, 60 million small-capacity injections / year, 30 million freeze-dried powder needles / year, sterile API 5000 kg / year, annual output value of hundreds of millions of yuan.
combined with the characteristics of the three enterprises, there is a market view that part of the reason for Yuheng's move is to highlight the advantages of the core pipeline, divestiture benefits are not outstanding edge enterprises.the
, there may be a deeper reason for the total divestiture of the three subsidiaries.
since February 2017, Yuheng Pharmaceuticals' share price has continued to fall from more than 9 yuan to about 5.7 yuan in early February this year, and its share price has fallen by more than 20% and its net profit has fallen significantly.
the same time, Yuheng Pharmaceuticals in recent years a large number of mergers and acquisitions are slowly showing the after-effects. According to the announcement, Yu Heng recently invested heavily in the acquisition of Guangzhou Xinhuacheng Biotech Co., Ltd. ("Flower City Bio"), Dandelion Pharmaceuticals, Nanjing Wanchuan, Shanghai Huato, Shanxi Pude Pharmaceuticals, Ono (China), Sunyang Zhenyang Hospital and other pharmaceutical and medical assets. Among them, Shanghai Huato, Nanjing Wanchuan, Shanxi Pude Pharmaceuticals, Ono (China), etc., are 100% shareholding.
among them, the first acquisition of Shanxi Pude Pharmaceuticals 85.01% of the shares, the price reached 2.38 billion yuan, the second acquisition of the remaining shares, the price reached 387 million yuan, while the acquisition of Shanghai Huato price close to 800 million yuan.
Under financial pressure, there is a view that The divestiture of the three subsidiaries, including Shanghai Huato, Shanxi Pude are in previous years mergers and acquisitions, revenue, assets accounted for a higher proportion of listed companies, the acquisition involved nearly 3 billion, Yuheng this "suffering" to sell it, perhaps another reason is to achieve rapid withdrawal of funds. (Seber Blue)